BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26509654)

  • 1. ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.
    Fernández NB; Lorenzo D; Picco ME; Barbero G; Dergan-Dylon LS; Marks MP; García-Rivello H; Gimenez L; Labovsky V; Grumolato L; Lopez-Bergami P
    Mol Carcinog; 2016 Nov; 55(11):1772-1785. PubMed ID: 26509654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
    Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
    Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
    Mao Y; Xu L; Wang J; Zhang L; Hou N; Xu J; Wang L; Yang S; Chen Y; Xiong L; Zhu J; Fan W; Xu J
    Biofactors; 2019 May; 45(3):416-426. PubMed ID: 30801854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
    Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
    PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
    Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
    PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The signaling pathways activated by ROR1 in cancer.
    Quezada MJ; Lopez-Bergami P
    Cell Signal; 2023 Apr; 104():110588. PubMed ID: 36621728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
    Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
    PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.
    Zhang S; Chen L; Wang-Rodriguez J; Zhang L; Cui B; Frankel W; Wu R; Kipps TJ
    Am J Pathol; 2012 Dec; 181(6):1903-10. PubMed ID: 23041612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
    Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.
    Bosserhoff AK; Ellmann L; Quast AS; Eberle J; Boyle GM; Kuphal S
    Mol Carcinog; 2014 Aug; 53(8):635-47. PubMed ID: 23625515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.
    Liu ZJ; Xiao M; Balint K; Smalley KS; Brafford P; Qiu R; Pinnix CC; Li X; Herlyn M
    Cancer Res; 2006 Apr; 66(8):4182-90. PubMed ID: 16618740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling.
    Montenegro RC; de Vasconcellos MC; Barbosa Gdos S; Burbano RM; Souza LG; Lemos TL; Costa-Lotufo LV; de Moraes MO
    Toxicol In Vitro; 2013 Oct; 27(7):2076-83. PubMed ID: 23912027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
    Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.
    Wang J; Li L; Liu S; Zhao Y; Wang L; Du G
    Oncotarget; 2016 Dec; 7(51):84375-84387. PubMed ID: 27533251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.
    Hojjat-Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat AA; Mahmoudian J; Jeddi-Tehrani M; Rabbani H; Mellstedt H
    PLoS One; 2013; 8(4):e61167. PubMed ID: 23593420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
    O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
    Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.